Phosphodiesterase‑5 inhibitors and Alzheimer’s disease; a meta‑analysis on clinical studies
Abstract
Abstract To evaluate the potential therapeutic benefits of phosphodiesterase-5 inhibitors (PDE5Is) on Alzheimer’s disease (AD), electronic databases Embase, Scopus, and Medline were systematically searched from inception to March 18th, 2024. Studies assessing the association between the use of PDE5Is and AD incidence were included. Random-effects model of restricted maximum likelihood estimator was used to pool data. Seven studies were reviewed comprising 4,833,558 individuals, of which 348,546 received treatment with one of the PDE5Is. Pooled hazard ratios (HR) for AD incidence, comparing PDE5Is with no drug use (HR = 0.47, 95% CI 0.26–0.82, p-value: 0.01), and PDE5Is with no drug or drugs not in trial for AD (HR = 0.41, 95% CI 0.33–0.52, p-value: <0.01) were calculated. Synthesized evidence indicates PDE5Is administration is associated with AD risk reduction, supporting conduct of phase 3 clinical trials.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.